Cyclerion Therapeutics, Inc. (CYCN) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.
Analysts estimate Earnings Per Share (EPS) of $-30.00 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.21 vs est $-30.00 (beat +96%). 2025: actual $-1.09 vs est $-1.34 (beat +18.7%). Analyst accuracy: 0%.
CYCN Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to Cyclerion Therapeutics, Inc. in the past 3 months
EPS Estimates — CYCN
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.21
vs Est –$30.00
▲ 2,379.3% off
2025
Actual –$1.09
vs Est –$1.34
▲ 22.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CYCN
77%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.002B
vs Est $0.002B
▼ 0.0% off
2025
Actual $0.002B
vs Est $0.001B
▲ 47.0% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
